RxSight, Inc. Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; filed February 28, 2024. The filing reports annual results, with selected fourth-quarter operating metrics. RxSight is a commercial-stage medical technology company that sells the RxSight Light Adjustable Lens (LAL), Light Delivery Device (LDD), and related accessories for customized vision correction after cataract surgery.
Business Context and Operating Metrics
- The company primarily markets in the United States under a “razor and razor blade” model: LDD placements generate recurring LAL utilization.
- At December 31, 2023, the installed LDD base was 666, up from 400 at December 31, 2022.
- 2023 LAL implants totaled 54,873, up from 25,284 in 2022. Fourth-quarter 2023 LAL implants were 18,071 versus 9,123 in the prior-year quarter.
- 2023 LDD sales were 266, compared with 195 in 2022; fourth-quarter sales were 77 versus 57 in the prior-year quarter.
- The company had 374 full-time employees at December 31, 2023 and operates primarily from four facilities totaling approximately 121,000 square feet in Aliso Viejo, California.
Financial Performance and Liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $89.1 million | $49.0 million | Up 81.8% |
| LDD revenue | $32.1 million | $22.5 million | Up 42.5% |
| LAL revenue | $54.1 million | $25.0 million | Up 116.7% |
| Gross profit | $53.8 million | $21.3 million | Up 152.1% |
| Gross margin | 60.4% | 43.5% | Up 16.9 percentage points |
| Loss from operations | $(50.1) million | $(63.3) million | Loss narrowed |
| Operating margin | (56.2%) | (129.2%) | Improved |
| Net loss | $(48.6) million | $(66.8) million | Loss narrowed 27.2% |
| Net loss per share | $(1.41) | $(2.41) | Improved |
| Cash flow from operations | $(41.6) million | $(58.9) million | Cash burn reduced |
- Net loss margin was approximately (54.6%), compared with approximately (136.2%) in 2022.
- SG&A increased 27.5% to $74.8 million, driven primarily by additional selling and marketing personnel, compensation, commissions, stock-based compensation, post-market study costs, and public-company expenses.
- Research and development expense increased 11.8% to $29.1 million.
- At December 31, 2023, cash and cash equivalents were $9.7 million and short-term investments were $117.5 million, for total cash, cash equivalents and short-term investments of $127.2 million.
- Total liabilities were $22.2 million, including $3.0 million of lease liabilities. The Oxford term loan was fully repaid in August 2023; no term loan remained outstanding at year-end.
- Cash flow from investing activities was $(22.1) million, including $17.3 million of net short-term investment purchases and $4.8 million of capital expenditures.
- Cash flow from financing activities was $61.5 million, primarily from equity offerings, partially offset by $40.0 million of term-loan repayments.
- Accumulated deficit was $594.6 million at year-end. Federal net operating loss carryforwards were approximately $311.2 million, subject to expiration and potential ownership-change limitations.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven by a 29,589-unit increase in LAL sales and a 71-unit increase in LDD sales, reflecting broader adoption and a larger installed base.
- Gross margin expanded substantially because of operating leverage, a higher mix of LAL revenue, and lower LDD material costs following introduction of the compact LDD.
- Operating losses narrowed despite continued investment in commercial expansion, research and development, and clinical activities.
- Interest income increased to $6.6 million from $1.5 million due to higher interest rates and larger short-term investment balances.
- The company incurred a $1.8 million loss on extinguishment of debt but expects the debt payoff to reduce 2024 interest expense by approximately $2.3 million.
- Shares outstanding increased to 36.1 million from 28.3 million, primarily due to a February 2023 public offering, ATM sales, option exercises, and employee equity plans.
- The company ceased to qualify as an emerging growth company and became a large accelerated filer as of December 31, 2023, increasing public-company compliance requirements and costs.
Outlook, Commentary, Risks, and Unusual Items
- Management expects continued revenue growth from expanding the LDD installed base, increasing LAL utilization, adding sales and clinical personnel, and expanding customer education and marketing.
- The company expects continued net losses and negative operating cash flow in the near term while it invests in sales, marketing, research and development, clinical studies, regulatory compliance, and manufacturing capacity.
- Management states that existing cash, cash equivalents, short-term investments, and anticipated product sales should fund operations for at least 12 months after filing. It does not currently anticipate needing additional capital or debt to reach operating profitability, but this expectation depends on assumptions that may prove incorrect.
- No specific revenue, earnings, or margin guidance is provided in the filing.
- The company is conducting a 500-eye post-approval study and anticipates completing enrollment in 2024.
- Key risks include continued operating losses, uncertain timing of profitability, dependence on adoption by ophthalmic surgeons and patient willingness to pay, competition from larger IOL manufacturers, reimbursement and healthcare-policy changes, product liability, regulatory compliance, clinical-study outcomes, intellectual-property challenges, cybersecurity, and reliance on single- or sole-source suppliers.
- Supply-chain constraints, higher input costs, extended lead times, and potential supplier disruptions remain material risks. The company has no long-term supply agreements or guaranteed commitments with many suppliers.
- All cash, cash equivalents, and short-term investments are maintained with one financial institution; a portion is above FDIC insurance limits.
- No material litigation or regulatory matter was considered probable or reasonably estimable at December 31, 2023. The company states that it had not experienced a material cybersecurity incident as of the filing date.
- Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting. Management concluded that disclosure controls and internal controls were effective.
Important Facts for Investors to Verify
- Whether LDD placements and LAL utilization continue to grow at rates sufficient to offset expanding SG&A, R&D, clinical, and compliance expenses.
- The timing and probability of achieving operating profitability without additional equity or debt financing.
- Cash consumption, working-capital requirements, and the sustainability of the $127.2 million liquidity balance.
- The impact of equity issuance and stock-based compensation on future share dilution; 6.8 million options and 650,357 unvested RSUs were outstanding or unvested at year-end.
- Gross-margin progression as the product mix shifts toward LALs and manufacturing efficiencies are realized.
- Enrollment and results of the post-approval clinical study and any additional regulatory requirements.
- Reimbursement policies, patient out-of-pocket demand, and the effect of competing products from Alcon, Johnson & Johnson Vision, and Bausch + Lomb.
- Supplier concentration, manufacturing capacity, facility lease renewals, and exposure to supply-chain disruption.
- Potential limitations on NOL utilization under Sections 382 and 383 of the Internal Revenue Code.